tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

NAMS Stock Latest News

NewAmsterdam Pharma Appoints Adele Gulfo to Board
Company AnnouncementsNewAmsterdam Pharma Appoints Adele Gulfo to Board
17d ago
8K
NAMS
NewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim
PremiumThe Fly
NewAmsterdam Pharma price target raised to $41 from $35 at Guggenheim
2M ago
NAMS
NewAmsterdam Pharma: Buy Rating Backed by Promising Obicetrapib Trials and Strong Financial Position
PremiumRatings
NewAmsterdam Pharma: Buy Rating Backed by Promising Obicetrapib Trials and Strong Financial Position
2M ago
NAMS
NewAmsterdam Pharma files $500M mixed securities shelf
PremiumThe Fly
NewAmsterdam Pharma files $500M mixed securities shelf
2M ago
NAMS
NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress
PremiumCompany Announcements
NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress
2M ago
NAMS
NewAmsterdam Pharma price target raised to $52 from $47 at Scotiabank
PremiumThe FlyNewAmsterdam Pharma price target raised to $52 from $47 at Scotiabank
2M ago
NAMS
Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence
Premium
Company Announcements
Newamsterdam Pharma Faces Potential Investor Risks Due to Shareholder Influence
2M ago
NAMS
Promising Outlook for NewAmsterdam Pharma: Buy Rating Affirmed Amid Successful Trials and Strong Financial Position
Premium
Ratings
Promising Outlook for NewAmsterdam Pharma: Buy Rating Affirmed Amid Successful Trials and Strong Financial Position
2M ago
NAMS
Promising Drug Developments and Positive Trial Results Drive Buy Rating for NewAmsterdam Pharma
PremiumRatings
Promising Drug Developments and Positive Trial Results Drive Buy Rating for NewAmsterdam Pharma
2M ago
NAMS
NewAmsterdam reports FY24 revenue $45.56M, consensus $31.13M
PremiumThe Fly
NewAmsterdam reports FY24 revenue $45.56M, consensus $31.13M
2M ago
NAMS
NewAmsterdam Pharma Achieves Key Milestones in 2024
PremiumCompany Announcements
NewAmsterdam Pharma Achieves Key Milestones in 2024
4M ago
8K
NAMS
NewAmsterdam Pharma outlines 2025 strategic priorities
PremiumThe Fly
NewAmsterdam Pharma outlines 2025 strategic priorities
4M ago
NAMS
Annexon appoints William Jones to board of directors
PremiumThe FlyAnnexon appoints William Jones to board of directors
4M ago
ANNX
NAMS
Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz
Premium
The Fly
Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz
4M ago
T
BA
American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls
Premium
The Fly
American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls
4M ago
AAL
JWN
NewAmsterdam Pharma initiated with a Buy at H.C. Wainwright
PremiumThe Fly
NewAmsterdam Pharma initiated with a Buy at H.C. Wainwright
4M ago
NAMS
Esperion initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Esperion initiated with an Overweight at Cantor Fitzgerald
5M ago
ESPR
NAMS
Menarini announces topline data from Phase 3 BROADAY, TANDEM trials
PremiumThe Fly
Menarini announces topline data from Phase 3 BROADAY, TANDEM trials
5M ago
NAMS
NewAmsterdam Pharma’s $452.6M Public Offering Success
PremiumCompany Announcements
NewAmsterdam Pharma’s $452.6M Public Offering Success
5M ago
8K
NAMS
NewAmsterdam Pharma 12.12M share Secondary priced at $24.50
PremiumThe FlyNewAmsterdam Pharma 12.12M share Secondary priced at $24.50
5M ago
NAMS
Esperion selloff continues following competitor data from NewAmsterdam
Premium
The Fly
Esperion selloff continues following competitor data from NewAmsterdam
5M ago
ESPR
NAMS
NewAmsterdam Pharma price target raised to $47 from $35 at Scotiabank
Premium
The Fly
NewAmsterdam Pharma price target raised to $47 from $35 at Scotiabank
5M ago
NAMS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >